Glucan-induced keratoderma in acquired immunodeficiency syndrome

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) are conditions affecting the immune system.
• Soluble glucan (beta-1-3 polyglucose) is a substance derived from yeast and fungal cell walls.
• Keratoderma is a condition characterized by thickening of the skin on the palms and soles.

Observation:

• A significant correlation was observed between intravenous soluble glucan therapy and the development of keratoderma.
• Six out of 20 patients with AIDS or ARC receiving soluble glucan developed this specific skin eruption.
• The keratoderma appeared within two weeks of therapy initiation and resolved post-discontinuation.

Findings:

• The observed keratoderma differed from previously documented keratoderma blennorrhagica in AIDS-associated psoriasis.
• No similar keratoderma was noted in 735 patients with AIDS or ARC not receiving soluble glucan.
• The study highlights a highly significant correlation between glucan administration and hyperkeratosis.

Implications:

• Soluble glucan can induce a distinct dermatological reaction pattern, particularly in immunocompromised individuals with AIDS.
• Understanding this reaction is important for managing patients with AIDS undergoing therapies involving glucan or similar compounds.
• While the reaction may be specific to AIDS patients, the general principle of glucan-induced reactions warrants further investigation.